Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1206 vs Xgeva in Bone Metastases
NCT04550949Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QL1206 in bone metastases, sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
QL1206
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT04550949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550949.